Alemtuzumab er et genetisk fremstillet, humaniseret IgG1 kappa monoklonalt antistof specifikt for et 21- 28 kD lymfocyt- celleoverfladeglykoprotein (CD52).
Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52).